Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer

Clinical Cancer Research

Volumn 16, Issue 2, 2010, Pages 566-576

  Purcell, James W ^a   Davis, Jefferson ^a   Reddy, Mamatha ^a   Martin, Shamra ^a   Samayoa, Kimberly ^a   Vo, Hung ^a   Thomsen, Karen ^a   Bean, Peter ^a   Kuo, Wen Lin ^b   Ziyad, Safiyyah ^b   Billig, Jessica ^b   Feiler, Heidi S ^b   Gray, Joe W ^b   Wood, Kenneth W ^a   Cases, Sylvaine ^a  

^a Cytokinetics Inc   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOXORUBICIN; ISPINESIB; IXABEPILONE; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; MITOSIS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KINESIN; MICE; MICE, NUDE; MICE, SCID; QUINAZOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 74549223522     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1498     Document Type: Article

References (44)

1. Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999;17: 2355-64.
2. Nabholtz JM, Riva A. Taxane/anthracycline combinations: setting a new standard in breast cancer? Oncologist 2001;6 Suppl 3:5-12.
3. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20:1-15.
4. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007; 7:107-17.
5. Sawin KE, LeGuellec K, Philippe M, Mitchison TJ. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature 1992; 359:540-3.
6. Sakowicz R, Finer JT, Beraud C, et al. Anti-tumour activity of a kinesin inhibitor. Cancer Res 2004;64:3276-80.
7. Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995;83:1159-69.
8. Tao W, South VJ, Diehl RE, et al. An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Mol Cell Biol 2007;27:689-98.
9. Tao W, South VJ, Zhang Y, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005;8:49-59.
10. Shi J, Orth JD, Mitchison TJ. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 2008;68:3269-76.
11. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008;14:111-22.
12. Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? J Cell Sci 2009;122:2579-85.
13. Lad L, Luo L, Carson JD, et al. Mechanism of inhibition of human KSP by ispinesib. Biochemistry 2008;47:3576-85.
14. Burris HA, Lorusso P, Jones S, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. J Clin Oncol 2004 ASCO Annual Meeting Proceedings 2004;22:2004.
15. Beekman KW, Dunn R, Colevas D, et al. University of Chicago Consortium phase II study of ispinesib (SB-715992) in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol 2007 ASCO Annual Meeting Proceedings 2007;25:15573.
16. Chu Q, Holen KD, Rowinsky EK, et al. A phase I study of novel kinesin spindle protein (KSP) inhibitor, SB-715992 administered intravenously once every 21 days. J Clin Oncol 2004 ASCO Annual Meeting Proceedings 2004;22:2078.
17. Knox JJ, Gill S, Synold TW, et al. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs 2008;26: 265-72.
18. Lee CW, Belanger K, Rao SC, et al. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2008;26:249-55.
19. LoRusso JB, Jones JB, Gadgeel S, et al. A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB-715992, a novel kinesin spindle protein (KSP) inhibitor, on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors. European Cancer Conference 2003.
20. Miller K, Ng C, Ang P, et al. Phase II, open label study of SB-715992 (ispinesib) in subjects with advanced or metastatic breast cancer [abstract 1089]. San Antonio (TX): 28th Annual San Antonio Breast Cancer Symposium; 2005.
21. Shahin MS, Braly P, Rose P, et al. A phase II, open-label study of ispinesib (SB-715992) in patients with platinum/taxane refractory or resistant relapsed ovarian cancer. J Clin Oncol 2007 ASCO Annual Meeting Proceedings 2007;25 Part I:5562.
22. Tang PA, Siu LL, Chen EX, et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2008;26:257-64.
23. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
24. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-66.
25. Jackson JR, Gilmartin AG, Williams T, et al. A pharmacodynamic marker of mitosis demonstrates the anti-mitotic activity of SB-715992, an inhibitor of the mitotic kinesin KSP. Proc Am Assoc Cancer Res 2002;43:1336.
26. Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res 1998;58:1609-15.
27. Dutta A, Chandra R, Leiter LM, Lester S. Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc Natl Acad Sci U S A 1995;92:5386-90.
28. Lew DJ, Dulic V, Reed SI. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 1991;66:1197-206.
29. Kurebayashi J, Otsuki T, Tang CK, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer 1999;79:707-17.
30. Johnson RK, McCabe FL, Cauder E, et al. SB-715992, a potent and selective inhibitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. Proc Am Assoc Cancer Res 2002;43:1335.
31. 2 and mitosis. Cytometry 1998;32: 71-7.
32. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist 2006;11:1047-57.
33. Higgins B, Kolinsky K, Linn M, et al. Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. Anticancer Res 2007;27:2279-87.
34. O'Brien C, Cavet G, Pandita A, et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 2008;68:5380-9.
35. Smith AP, Henze M, Lee JA, et al. Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland. Oncogene 2006;25:7245-59.
36. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25:3421-7.
37. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14.
38. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58:2825-31.
39. Lee S, Yang W, Lan KH, et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 2002;62:5703-10.
40. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
41. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
42. Gomez H, Castaneda C, Philco M, et al. A phase I-II trial of ispinesib, a kinesin spindle protein inhibitor, dosed every two weeks in patients with locally advanced or metastatic breast cancer previously untreated with chemotherapy for metastatic disease or recurrence [abstract 2148]. San Antonio (TX): 31st Annual San Antonio Breast Cancer Symposium; 2008.
43. Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008;19:212-22.
44. Rodon J, Till E, Patnaik A, et al. Phase I study of ispinesib in combination with capecitabine in patients with advanced solid tumors. Prague (Czech Republic): 18th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2006.